Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2025 | 2543 | 1.240 |
Why?
|
| Breast Neoplasms | 18 | 2024 | 3155 | 1.080 |
Why?
|
| Pyridines | 8 | 2021 | 302 | 1.060 |
Why?
|
| Triple Negative Breast Neoplasms | 6 | 2025 | 191 | 0.920 |
Why?
|
| Kidney Neoplasms | 7 | 2019 | 531 | 0.780 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 2301 | 0.700 |
Why?
|
| Receptor, ErbB-2 | 6 | 2023 | 280 | 0.660 |
Why?
|
| Carcinoma, Renal Cell | 5 | 2019 | 357 | 0.600 |
Why?
|
| Neoadjuvant Therapy | 8 | 2024 | 446 | 0.560 |
Why?
|
| Capecitabine | 4 | 2024 | 97 | 0.550 |
Why?
|
| Benzenesulfonates | 2 | 2008 | 49 | 0.520 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2024 | 512 | 0.410 |
Why?
|
| Watchful Waiting | 3 | 2024 | 70 | 0.390 |
Why?
|
| Enzyme Inhibitors | 2 | 2007 | 638 | 0.390 |
Why?
|
| Carcinoma, Small Cell | 2 | 2017 | 115 | 0.370 |
Why?
|
| Prostatic Neoplasms | 5 | 2022 | 1769 | 0.370 |
Why?
|
| Lung Neoplasms | 5 | 2018 | 2363 | 0.360 |
Why?
|
| Comparative Effectiveness Research | 1 | 2012 | 57 | 0.360 |
Why?
|
| Urologic Neoplasms | 2 | 2024 | 78 | 0.360 |
Why?
|
| Middle Aged | 32 | 2025 | 27535 | 0.330 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 244 | 0.330 |
Why?
|
| Aged | 28 | 2025 | 20395 | 0.330 |
Why?
|
| Bevacizumab | 8 | 2022 | 254 | 0.330 |
Why?
|
| Students, Medical | 3 | 2023 | 433 | 0.320 |
Why?
|
| Neoplasms | 6 | 2023 | 3168 | 0.320 |
Why?
|
| Neoplasm Staging | 11 | 2025 | 2009 | 0.310 |
Why?
|
| Medical Oncology | 3 | 2019 | 403 | 0.310 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 7039 | 0.310 |
Why?
|
| Radiosurgery | 3 | 2021 | 319 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2016 | 916 | 0.300 |
Why?
|
| Receptors, Estrogen | 3 | 2024 | 412 | 0.290 |
Why?
|
| Anilides | 3 | 2019 | 45 | 0.290 |
Why?
|
| Humans | 50 | 2025 | 93132 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 1130 | 0.280 |
Why?
|
| Female | 35 | 2025 | 48542 | 0.270 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 195 | 0.270 |
Why?
|
| Prostatectomy | 2 | 2021 | 472 | 0.260 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 308 | 0.250 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 57 | 0.250 |
Why?
|
| Adult | 23 | 2025 | 27849 | 0.240 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 302 | 0.240 |
Why?
|
| Pyrroles | 2 | 2017 | 165 | 0.230 |
Why?
|
| Disease-Free Survival | 7 | 2024 | 1171 | 0.230 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2019 | 180 | 0.220 |
Why?
|
| Indoles | 2 | 2017 | 298 | 0.220 |
Why?
|
| Neutropenia | 3 | 2021 | 209 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1447 | 0.210 |
Why?
|
| Nitriles | 3 | 2024 | 154 | 0.210 |
Why?
|
| Trastuzumab | 2 | 2021 | 86 | 0.210 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 603 | 0.200 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 376 | 0.190 |
Why?
|
| Piperazines | 2 | 2021 | 284 | 0.190 |
Why?
|
| Aspirin | 1 | 2024 | 164 | 0.190 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2024 | 154 | 0.190 |
Why?
|
| Androgen Antagonists | 2 | 2021 | 143 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 570 | 0.190 |
Why?
|
| Vegetables | 2 | 2020 | 50 | 0.180 |
Why?
|
| Interdisciplinary Studies | 2 | 2019 | 19 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 249 | 0.180 |
Why?
|
| ErbB Receptors | 1 | 2005 | 504 | 0.180 |
Why?
|
| Schools, Medical | 2 | 2023 | 131 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 223 | 0.180 |
Why?
|
| Paclitaxel | 5 | 2025 | 478 | 0.170 |
Why?
|
| Clinical Competence | 2 | 2018 | 810 | 0.170 |
Why?
|
| Oxazoles | 1 | 2021 | 13 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2023 | 110 | 0.170 |
Why?
|
| Double-Blind Method | 5 | 2024 | 1727 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2024 | 1000 | 0.170 |
Why?
|
| Male | 21 | 2024 | 44355 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 151 | 0.160 |
Why?
|
| Oncologists | 1 | 2021 | 38 | 0.160 |
Why?
|
| Postmenopause | 2 | 2024 | 106 | 0.160 |
Why?
|
| Triazoles | 2 | 2024 | 110 | 0.160 |
Why?
|
| Quinazolines | 1 | 2021 | 211 | 0.160 |
Why?
|
| Leukemia | 1 | 2022 | 300 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 202 | 0.150 |
Why?
|
| Testosterone | 1 | 2021 | 258 | 0.150 |
Why?
|
| Treatment Outcome | 9 | 2025 | 9070 | 0.150 |
Why?
|
| Neoplasm Metastasis | 4 | 2016 | 1060 | 0.140 |
Why?
|
| Age Factors | 1 | 2023 | 1898 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2021 | 278 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2019 | 124 | 0.140 |
Why?
|
| Diet | 2 | 2022 | 461 | 0.140 |
Why?
|
| Palliative Medicine | 1 | 2018 | 11 | 0.140 |
Why?
|
| Counseling | 1 | 2020 | 164 | 0.140 |
Why?
|
| Survival Analysis | 4 | 2021 | 1518 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2023 | 4546 | 0.130 |
Why?
|
| Niacinamide | 2 | 2008 | 101 | 0.130 |
Why?
|
| Disease Progression | 5 | 2021 | 1529 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2008 | 97 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 99 | 0.130 |
Why?
|
| Curriculum | 2 | 2019 | 590 | 0.130 |
Why?
|
| Survival Rate | 5 | 2019 | 1945 | 0.120 |
Why?
|
| Carboplatin | 4 | 2022 | 321 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 1660 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 1385 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3450 | 0.120 |
Why?
|
| Health Services Misuse | 1 | 2016 | 20 | 0.120 |
Why?
|
| Prognosis | 5 | 2023 | 3890 | 0.120 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 221 | 0.120 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 3814 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2016 | 167 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 425 | 0.100 |
Why?
|
| Pediatrics | 1 | 2018 | 378 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2018 | 336 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 1171 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 304 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2024 | 874 | 0.100 |
Why?
|
| Young Adult | 5 | 2024 | 6922 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 450 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 888 | 0.090 |
Why?
|
| Quality of Life | 4 | 2022 | 1776 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2024 | 80 | 0.080 |
Why?
|
| Hospitalization | 1 | 2016 | 924 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 176 | 0.080 |
Why?
|
| Fatigue | 3 | 2017 | 181 | 0.080 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1098 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2018 | 1074 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 1719 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 205 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 233 | 0.070 |
Why?
|
| Oncogenes | 1 | 2007 | 100 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1908 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 10128 | 0.060 |
Why?
|
| Prostate-Specific Antigen | 2 | 2020 | 337 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 873 | 0.060 |
Why?
|
| Deoxycytidine | 2 | 2021 | 207 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2007 | 515 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2019 | 913 | 0.050 |
Why?
|
| Mifepristone | 1 | 2025 | 50 | 0.050 |
Why?
|
| Thrombocytopenia | 2 | 2017 | 189 | 0.050 |
Why?
|
| Albumins | 1 | 2025 | 123 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 827 | 0.050 |
Why?
|
| United States | 3 | 2024 | 7581 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 66 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2023 | 3044 | 0.050 |
Why?
|
| Canada | 1 | 2024 | 194 | 0.050 |
Why?
|
| Contrast Media | 1 | 2008 | 986 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5900 | 0.050 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 144 | 0.050 |
Why?
|
| Abiraterone Acetate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2024 | 655 | 0.050 |
Why?
|
| Cancer Survivors | 1 | 2024 | 90 | 0.050 |
Why?
|
| Prednisone | 1 | 2023 | 242 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2024 | 305 | 0.050 |
Why?
|
| Time Factors | 2 | 2021 | 5380 | 0.050 |
Why?
|
| Mastectomy, Segmental | 1 | 2023 | 108 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 314 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 2787 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2021 | 64 | 0.040 |
Why?
|
| Radiation Oncologists | 1 | 2021 | 15 | 0.040 |
Why?
|
| Breast | 1 | 2023 | 302 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2021 | 87 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 196 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Perception | 1 | 2021 | 178 | 0.040 |
Why?
|
| Learning | 1 | 2023 | 289 | 0.040 |
Why?
|
| Hypertension | 2 | 2017 | 748 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 36 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 262 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2019 | 241 | 0.040 |
Why?
|
| Cisplatin | 1 | 2021 | 567 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 353 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 234 | 0.040 |
Why?
|
| Prostate | 1 | 2022 | 416 | 0.040 |
Why?
|
| Tamoxifen | 1 | 2019 | 170 | 0.030 |
Why?
|
| Training Support | 1 | 2018 | 22 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 116 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2018 | 23 | 0.030 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 23 | 0.030 |
Why?
|
| Hemoptysis | 1 | 2018 | 25 | 0.030 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 35 | 0.030 |
Why?
|
| Celecoxib | 1 | 2017 | 33 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2017 | 71 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2017 | 75 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 258 | 0.030 |
Why?
|
| Platinum Compounds | 1 | 2017 | 29 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 236 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 18 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 381 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2007 | 3497 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2018 | 312 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 33 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 91 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 709 | 0.030 |
Why?
|
| Selection Bias | 1 | 2016 | 37 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 129 | 0.030 |
Why?
|
| Standard of Care | 1 | 2016 | 69 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1866 | 0.030 |
Why?
|
| Transcriptome | 1 | 2020 | 762 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 145 | 0.030 |
Why?
|
| Biomarkers | 1 | 2021 | 1905 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 278 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1697 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 1172 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 283 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2020 | 2434 | 0.020 |
Why?
|
| Remission Induction | 1 | 2014 | 737 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2484 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2016 | 581 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2011 | 524 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7273 | 0.020 |
Why?
|
| Chicago | 1 | 2011 | 1452 | 0.020 |
Why?
|
| Mutation | 1 | 2012 | 4265 | 0.010 |
Why?
|